Study identification

EU PAS number

EUPAS1000000815

Study ID

1000000815

Official title and acronym

DARWIN EU® - Characterisation of systemic treatments for the management of ovarian cancer

DARWIN EU® study

Yes

Study countries

Denmark
France
Netherlands
Norway

Study description

Ovarian cancer remains a significant health concern in Europe, resulting in more deaths than any other gynaecological cancer. Treatment strategies for ovarian cancer include surgery, chemotherapy, and targeted therapies that are selected based on patient characteristics, as well as type and stage of cancer.
Chemotherapy drugs include alkylating agents, anthracyclines, antimetabolites, platinum-based drugs, taxanes, and other targeted therapies, such as poly (ADP-ribose) polymera (PARP) inhibitors, hormonal agents, and anti-angiogenesis drugs (Bevacizumab).
The aim of this study is to inform which authorised systemic treatments are actively being used as a treatment for epithelial ovarian cancer.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Anum Zahra

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable